Cartesian Therapeutics (RNAC) Tax Rate (2021 - 2022)
Cartesian Therapeutics (RNAC) posted quarterly Tax Rate of 5.14% for Q4 2022, down 625.0% year-over-year from 0.98% in Q4 2021, and down 231.48% quarter-over-quarter from 3.91% in Q3 2022.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Tax Rate (2021 - 2022) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Tax Rate for 2 consecutive years, with 5.14% the latest figure, recorded in Q4 2022.
- In Q4 2022, Tax Rate fell 625.0% year-over-year to 5.14%; the TTM figure through Dec 2022 stood at 73.75% (down 65763.0% YoY), while the FY2025 annual figure was 6.6%, up 698.0% from the prior year.
- Tax Rate declined to 5.14% in Q4 2022 per RNAC's latest filing, from 3.91% in the prior quarter.
- Across five years, Tax Rate topped out at 3.91% in Q3 2022 and bottomed at 766.12% in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.98% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 15.11% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -10.89% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 24.15% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 7.49% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -16.71% |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -5.14% |
| Sep 30, 2022 | 3.91% |
| Dec 31, 2021 | 1.11% |
| Sep 30, 2021 | -766.12% |